---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-024432"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:55:32.138747+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elanco signs research agreement with WEDterinary for $4M gene therapy in cats; four directors departing

## Summary
- Board to shrink to 11 directors; Bilbrey, Turner, Wallace won't stand for re-election; Doyle resigned.
- Research agreement with WEDterinary (33%-owned by Doyle) for targeted gene therapy treating chronic kidney disease in cats.
- Elanco US will pay up to $4 million to fund WED research, securing negotiation rights to resulting IP.
- Doyle will continue advising Elanco on animal health innovation; Paul Herendeen to chair Finance Committee.
- Agreement funded within R&D operating expenses; approved by Audit Committee under related person policy.

## SEC filing metadata
- accession: 0001104659-25-024432
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465925024432/0001104659-25-024432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465925024432/tm259453d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-024432
- JSON: https://secwatch.observer/filing/0001104659-25-024432.json
- Plain text: https://secwatch.observer/filing/0001104659-25-024432.txt

## Key facts
- Executive change
  William F. Doyle resigned as Director at Elanco Animal Health Inc.
  - Action: resigned
  - Role: Director
  source text: the Company announced certain changes to its Board of Directors, including the decision by William F. Doyle to resign from the Board, effective upon the Company entering into a research agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000110465925024432/0001104659-25-024432-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.